Phase 1/2 Multiple Ascending Dose Trial of the Prostate-Specific Membrane Antigen (PSMA)-Targeted Antibody Drug Conjugate MLN2704 in Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: This phase 1/2 study evaluated the dose-limiting toxicity and maximum tolerated dose of MLN2704, a humanized monoclonal antibody MLN591 targeting prostate-specific membrane antigen, linked to the maytansinoid DM1 in patients with progressive metastatic castration-resistant prostate cance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Urol Oncol
Main Authors: Milowsky, Matthew I., Galsky, Matthew D., Morris, Michael J., Crona, Daniel J., George, Daniel J., Dreicer, Robert, Tse, Kin, Petruck, Jesika, Webb, Iain J., Bander, Neil H., Nanus, David M., Scher, Howard I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464417/
https://ncbi.nlm.nih.gov/pubmed/27765518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2016.07.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados